Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
复制标题
作者:
Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of estrogen receptor (ER)α. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERα-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ERα-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen-resistance. Furthermore, Aurora-A interacts with and phosphorylates ERα on serine-167 and -305, leading to increase in ERα DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ERα-positive but not -negative breast cancers. These data suggest that Aurora-A plays a pivotal role in tamoxifen resistance and ERα is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ERα-positive tumor and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.
登录
查看更多内容
影响因子:
8
作者:
通讯作者:
--
DOI:
10.2165/00129785-200404010-00003
发表时间:
2004-01-01
期刊:
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
影响因子:
--
作者:
Barkhem, Tomas;Nilsson, Stefan;Gustafsson, Jan-Ake
通讯作者:
Gustafsson, Jan-Ake
影响因子:
4.3
作者:
Holz, Marina K.
通讯作者:
Holz, Marina K.
影响因子:
4.8
作者:
Li, QY;Kaneko, S;Cheng, JQ
通讯作者:
Cheng, JQ
影响因子:
5.3
作者:
Lim, Kian-Huat;Brady, Donita C.;Counter, Christopher M.
通讯作者:
Counter, Christopher M.